Quarterly report pursuant to Section 13 or 15(d)

Revenue and Accounts Receivable - Additional Information (Details)

v3.10.0.1
Revenue and Accounts Receivable - Additional Information (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
USD ($)
company
Sep. 30, 2017
USD ($)
company
Sep. 30, 2018
USD ($)
company
Sep. 30, 2017
USD ($)
company
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Revenue $ 5,940 $ 8,028 $ 20,643 $ 21,598
Payor | Sales | 10% or More Clinical Revenue        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Percentage of benchmark 10.00%   10.00%  
Number of companies that accounted for approximately 10% or more of revenue | company 1 1 0 1
Payor | Sales | Customer One | 10% or More Clinical Revenue        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Percentage of benchmark   11.00%   11.00%
VivoPharm        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Revenue $ 535   $ 3,243  
Discovery Services        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Revenue 535 $ 980 3,525 $ 1,536
Discovery Services | VivoPharm        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Revenue   794   794
Clinical Services        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Revenue $ 1,555 $ 2,880 $ 6,019 $ 8,887
Revenue, payment terms     6 months  
Clinical Services And Discovery Services        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Revenue, timing of satisfaction of remaining performance obligation     In the case of Clinical Services and Discovery Services, the duration of performance obligation is less than one year.